CJC-1295 (with DAC) is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) with a significantly extended half-life compared to the version without DAC (Drug Affinity Complex).
CJC-1295: This is the base peptide, a synthetic version of GHRH, which naturally signals the pituitary gland to release growth hormone (GH). CJC-1295 works by mimicking this natural signal, causing your body to produce more of its own GH, leading to downstream increases in insulin-like growth factor 1 (IGF-1). IGF-1 is a key anabolic hormone crucial for muscle growth, fat metabolism, and cellular repair.
DAC (Drug Affinity Complex): This is a modification added to the CJC-1295 peptide. The DAC allows the peptide to bind to albumin, a protein in the blood plasma. This binding protects the peptide from rapid degradation, significantly extending its half-life to approximately 6-8 days.
CJC-1295 with DAC is a long-acting version of the peptide that continuously stimulates GH release due to its prolonged presence in the bloodstream. This means it requires fewer injections (typically 1-2 times per week) to maintain elevated levels of growth hormone and IGF-1.